Molecular and genetic features of colorectal carcinoma: pathomorphological demonstration of clinical cases and literature review

Authors

DOI:

https://doi.org/10.26641/1997-9665.2021.2.59-67

Keywords:

colorectal carcinoma, CyD1, HIF1α, LC3B, p21, p53, KRAS amplification, FISH

Abstract

Background. Colorectal carcinoma (CRC) is one of the most widespread malignancies worldwide; its morbidity rate is on the third place amidst the most common cancers. According to present data, such molecular markers as CyD1, HIF1α, LC3B, p21, p53 as well as the detection of KRAS gene amplification could be used for evaluation of tumor grade, its invasiveness, risk of metastases, sensitivity to anti-EGFR treatment, and further prognosis for patient’s survive. Objective. The purpose of this study was to make a literature review of the CRC molecular diagnostic approaches and demonstrate 5 cases of colorectal carcinoma in patients of Dnipro-city region in purpose to reveal their molecular-genetic features. Methods. Five formalin fixed paraffin embedded specimens of colorectal carcinoma from patients of Dnipro-city region were evaluated pathomorphologically with histological, immunohistochemical and fluorescence in situ hybridization methods. Results. Case study revealed increased level of p53, p21, and LC3B expression, minor elevation of CyD1 and HIF1α expression in demonstrated samples. Amplification of KRAS gene was not found. Conclusion. Our data analysis had revealed multiple studies dedicated to CRC molecular diagnostics with controversial results, what could be explained by both variable methodological approaches and epidemiological peculiarities of CRC in different sites of the globe. Therefore, there is a necessity in empirical identification of the molecular-genetic features of colorectal carcinomas in patients of our region that could improve current state of the art in CRC diagnostic and treatment approaches. Achieved data are the result of the trial and our research of this issue is ongoing.

References

  1. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017 Apr; 66(4): 683-691. doi: 10.1136/gutjnl-2015-310912. Epub 2016 Jan 27. PMID: 26818619.
  2. Melnitchouk N, Shabat G, Lu P, Lyu H, Scully R, Leung K, Jarman M, Lukashenko A, Kolesnik OO, Goldberg J, Davids JS, Bleday R. Colorectal Cancer in Ukraine: Regional Disparities and National Trends in Incidence, Management, and Mortality. J Glob Oncol. 2018 Oct; 4:1-8. doi: 10.1200/JGO.18.00145. PMID: 30354936; PMCID: PMC6657623.
  3. Nevins JR. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science. 1992 Oct 16; 258(5081):424-9. doi: 10.1126/science.1411535. PMID: 1411535.
  4. Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell. 2008 Feb; 14(2):159-69. doi: 10.1016/j.devcel.2008.01.013. PMID: 18267085.
  5. Bondi J, Husdal A, Bukholm G, Nesland JM, Bakka A, Bukholm IR. Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome. J Clin Pathol. 2005 May; 58(5):509-14. doi: 10.1136/jcp.2004.020347. PMID: 15858123; PMCID: PMC1770669.
  6. Ayhan S, Isisag A, Saruc M, Nese N, Demir MA, Kucukmetin NT. The role of pRB, p16 and cyclin D1 in colonic carcinogenesis. Hepatogastroenterology. 2010 Mar-Apr; 57(98):251-6. PMID: 20583423.
  7. Hulit J, Wang C, Li Z, Albanese C, Rao M, Di Vizio D, Shah S, Byers SW, Mahmood R, Augenlicht LH, Russell R, Pestell RG. Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. Mol Cell Biol. 2004 Sep; 24(17):7598-611. doi: 10.1128/MCB.24.17.7598-7611.2004. Erratum in: Mol Cell Biol. 2005 Jan;25(1):523. PMID: 15314168; PMCID: PMC507010.Hulit J, et al.
  8. Bahnassy AA, Zekri AR, El-Houssini S, El-Shehaby AM, Mahmoud MR, Abdallah S, El-Serafi M. Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients. BMC Gastroenterol. 2004 Sep 23; 4:22. doi: 10.1186/1471-230X-4-22. PMID: 15385053; PMCID: PMC524166.
  9. Ogino S, Nosho K, Irahara N, Kure S, Shima K, Baba Y, Toyoda S, Chen L, Giovannucci EL, Meyerhardt JA, Fuchs CS. A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. Clin Cancer Res. 2009 Jul 1; 15(13):4431-8. doi: 10.1158/1078-0432.CCR-08-3330. Epub 2009 Jun 23. PMID: 19549773; PMCID: PMC2921858.
  10. Lyall MS, Dundas SR, Curran S, Murray GI. Profiling markers of prognosis in colorectal cancer. Clin Cancer Res. 2006 Feb 15; 12(4):1184-91. doi: 10.1158/1078-0432.CCR-05-1864. PMID: 16489072.
  11. Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001 Feb 21; 93(4):266-76. doi: 10.1093/jnci/93.4.266. PMID: 11181773.
  12. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer. 2008 Dec; 8(12):967-75. doi: 10.1038/nrc2540. Epub 2008 Nov 6. PMID: 18987634; PMCID: PMC3140692.
  13. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992 Dec;12(12):5447-54. doi: 10.1128/mcb.12.12.5447-5454.1992. PMID: 1448077; PMCID: PMC360482.
  14. Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell. 2007 Apr; 11(4):335-47. doi: 10.1016/j.ccr.2007.02.006. PMID: 17418410; PMCID: PMC3145406.
  15. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, Zheng P, Ye K, Chinnaiyan A, Halder G, Lai ZC, Guan KL. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007 Nov 1; 21(21):2747-61.
  16. doi: 10.1101/gad.1602907. PMID: 17974916; PMCID: PMC2045129.
  17. Peng JK, Shen SQ, Wang J, Jiang HW, Wang YQ. Ηypoxia-inducible factor 1-α promotes colon cell proliferation and migration by upregulating AMPK-related protein kinase 5 under hypoxic conditions. Oncol Lett. 2018 Mar; 15(3):3639-3645. doi: 10.3892/ol.2018.7748. Epub 2018 Jan 8. PMID: 29467884; PMCID: PMC5796283.
  18. Nicolini A, Carpi A, Tarro G. Biomolecular markers of breast cancer. Front Biosci. 2006 May 1; 11:1818-43. doi: 10.2741/1926. PMID: 16368559.
  19. Han JS, Cao D, Molberg KH, Sarode VR, Rao R, Sutton LM, Peng Y. Hormone receptor status rather than HER2 status is significantly associated with increased Ki-67 and p53 expression in triple-negative breast carcinomas, and high expression of Ki-67 but not p53 is significantly associated with axillary nodal metastasis in triple-negative and high-grade non-triple-negative breast carcinomas. Am J Clin Pathol. 2011 Feb; 135(2):230-7. doi: 10.1309/AJCP9DV3EVZUATFV. PMID: 21228363.
  20. Yang Y, Li J, Jin L, Wang D, Zhang J, Wang J, Zhao X, Wu G, Yao H, Zhang Z. Independent Correlation Between Ki67 Index and Circulating Tumor Cells in the Diagnosis of Colorectal Cancer. Anticancer Res. 2017 Aug;37(8):4693-4700. doi: 10.21873/anticanres.11874. PMID: 28739773.
  21. Lopez G, Boggio F, Ferrero S, Fusco N, Del Gobbo A. Molecular and Immunohistochemical Markers with Prognostic and Predictive Significance in Liver Metastases from Colorectal Carcinoma. Int J Mol Sci. 2018 Oct 3; 19(10):3014. doi: 10.3390/ijms19103014. PMID: 30282914; PMCID: PMC6213422.
  22. Dawson H, Koelzer VH, Karamitopoulou E, Economou M, Hammer C, Muller DE, Lugli A, Zlobec I. The apoptotic and proliferation rate of tumour budding cells in colorectal cancer outlines a heterogeneous population of cells with various impacts on clinical outcome. Histopathology. 2014 Mar; 64(4):577-84. doi: 10.1111/his.12294. Epub 2013 Dec 28. PMID: 24111856.
  23. Xi HQ, Zhao P. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma. J Clin Pathol. 2011 Jun;64(6):498-503. doi: 10.1136/jcp.2010.087213. Epub 2011 Mar 17. PMID: 21415057.
  24. Heidari Z, Mahmoudzadeh-Sagheb H, Jahantigh M, Charkhat Gorgich E A. Immunohistochemical Expression of Ki67 and HER2 in Colorectal Cancer Compared to Adenomatous and Normal Samples. Int J Cancer Manag. 2017 ; 10(11):e12252. doi: 10.5812/ijcm.12252.
  25. Wu S, Sun C, Tian D, Li Y, Gao X, He S, Li T. Expression and clinical significances of Beclin1, LC3 and mTOR in colorectal cancer. Int J Clin Exp Pathol. 2015 Apr 1; 8(4):3882-91. PMID: 26097572; PMCID: PMC4466959.
  26. Choi JH, Cho YS, Ko YH, Hong SU, Park JH, Lee MA. Absence of autophagy-related proteins expression is associated with poor prognosis in patients with colorectal adenocarcinoma. Gastroenterology Research and Practice. 2014; 2014:179586. DOI: 10.1155/2014/179586.
  27. Ogino S, Nosho K, Shima K, Baba Y, Irahara N, Kirkner GJ, Hazra A, De Vivo I, Giovannucci EL, Meyerhardt JA, Fuchs CS. p21 expression in colon cancer and modifying effects of patient age and body mass index on prognosis. Cancer Epidemiol Biomarkers Prev. 2009 Sep; 18(9):2513-21. doi: 10.1158/1055-9965.EPI-09-0451. Epub 2009 Sep 1. PMID: 19723919; PMCID: PMC2758547.
  28. Gartel AL, Serfas MS, Tyner AL. p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med. 1996 Nov; 213(2):138-49. doi: 10.3181/00379727-213-44046. PMID: 8931660.
  29. Garner E, Raj K. Protective mechanisms of p53-p21-pRb proteins against DNA damage-induced cell death. Cell Cycle. 2008 Feb 1; 7(3):277-82. doi: 10.4161/cc.7.3.5328. Epub 2007 Nov 18. PMID: 18235223.
  30. Wang LL, Guo HH, Zhan Y, Feng CL, Huang S, Han YX, Zheng WS, Jiang JD. Specific up-regulation of p21 by a small active RNA sequence suppresses human colorectal cancer growth. Oncotarget. 2017 Apr 11; 8(15):25055-25065. doi: 10.18632/oncotarget.15918. PMID: 28445988; PMCID: PMC5421909.
  31. Salem A, Elfeky M, Nawar N, Alattar A, Elekiabi O, Elaidy M. Prognostic Value of Combined Cox-2, Cyclin D1 and P21 Expression in Colorectal Cancer (CRC) Patients: An Immunohistochemical Study. Open Journal of Pathology. 2018, 8(3), 106-121.
  32. Al-Maghrabi J, Al-Ahwal M, Buhmeida A, Syrjänen K, Sibyani A, Emam E, Ghanim A, Al-Qahtani M. Expression of cell cycle regulators p21 and p27 as predictors of disease outcome in colorectal carcinoma. J Gastrointest Cancer. 2012 Jun; 43(2):279-87. doi: 10.1007/s12029-011-9292-y. PMID: 21637966.
  33. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000 Apr 1; 60(7):1777-88. PMID: 10766157.
  34. McGregor MJ, Fadhil W, Wharton R, Yanagisawa Y, Presz M, Pritchard A, Womack C, Dutton S, Kerr RS, Kerr DJ, Johnstone EC, Ilyas M. Aberrant P53 expression lacks prognostic or predictive significance in colorectal cancer: results from the VICTOR trial. Anticancer Res. 2015 Mar;35(3):1641-5. PMID: 25750322.
  35. El-Guindy, Dina M, Mwafy, Shorouk E. Prognostic value of CD74 and p53 expression in colorectal cancer. Egypt J of Path. 2017 Dec; 37(2): 374-380. doi: 10.1097/01.XEJ.0000527755.42637.94
  36. Nikolouzakis TK, Vassilopoulou L, Fragkiadaki P, Mariolis Sapsakos T, Papadakis GZ, Spandidos DA, Tsatsakis AM and Tsiaoussis J. Improving diagnosis, prognosis and prediction by using biomarkers in CRC patients (Review). Oncol Rep 39: 2455-2472, 2018.
  37. Kullivan KM, Kozuch PS. Impact of KRAS Mutations on Management of Colorectal Carcinoma. Patholog Res Int. 2011; 2011:219309
  38. Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, Paraf F, Lauricella C, Dimartino V, Hobor S, Jacobs B, Ercolani C, Lamba S, Scala E, Veronese S, Laurent-Puig P, Siena S, Tejpar S, Mottolese M, Punt CJ, Gambacorta M, Bardelli A, Di Nicolantonio F. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int J Cancer. 2013 Sep 1; 133(5):1259-65. doi: 10.1002/ijc.28106. Epub 2013 Mar 16. PMID: 23404247.
  39. Dinu D, Dobre M, Panaitescu E, Bîrlă R, Iosif C, Hoara P, Caragui A, Boeriu M, Constantinoiu S, Ardeleanu C. Prognostic significance of KRAS gene mutations in colorectal cancer--preliminary study. J Med Life. 2014 Oct-Dec; 7(4):581-7. PMID: 25713627; PMCID: PMC4316144.
  40. Peluso G, Incollingo P, Calogero A, Tammaro V, Rupealta N, Chiacchio G, Sandoval Sotelo ML, Minieri G, Pisani A, Riccio E, Sabbatini M, Bracale UM, Dodaro CA, Carlomagno N. Current Tissue Molecular Markers in Colorectal Cancer: A Literature Review. Biomed Res Int. 2017; 2017:2605628. doi: 10.1155/2017/2605628. Epub 2017 Oct 29. PMID: 29214162; PMCID: PMC5682052.
  41. Ducreux M, Chamseddine A, Laurent-Puig P, Smolenschi C, Hollebecque A, Dartigues P, Samallin E, Boige V, Malka D, Gelli M. Molecular targeted therapy of BRAF-mutant colorectal cancer. Ther Adv Med Oncol. 2019 Jun 18; 11:1758835919856494. doi: 10.1177/1758835919856494. PMID: 31244912; PMCID: PMC6582307.
  42. Li W, Liu Y, Cai S, Yang C, Lin Z, Zhou L, Liu L, Cheng X, Zeng W. Not all mutations of KRAS predict poor prognosis in patients with colorectal cancer. Int J Clin Exp Pathol. 2019 Mar 1; 12(3):957-967. PMID: 31933906; PMCID: PMC6945179.
  43. Peluso G, Incollingo P, Calogero A, Tammaro V, Rupealta N, Chiacchio G, Sandoval Sotelo ML, Minieri G, Pisani A, Riccio E, Sabbatini M, Bracale UM, Dodaro CA, Carlomagno N. Current Tissue Molecular Markers in Colorectal Cancer: A Literature Review. Biomed Res Int. 2017; 2017:2605628. doi: 10.1155/2017/2605628. Epub 2017 Oct 29. PMID: 29214162; PMCID: PMC5682052.

Downloads

Published

2021-12-21

How to Cite

Molecular and genetic features of colorectal carcinoma: pathomorphological demonstration of clinical cases and literature review. (2021). Морфологія / Morphologia / Morfologìâ, 15(2), 59–67. https://doi.org/10.26641/1997-9665.2021.2.59-67

Issue

Vol. 15 No. 2 (2021)

Section

Статті

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

 The authors reserve the right to authorship of their work and transfer to the Journal the right to the first publication of this work under the terms of a license Creative commons Attribution 4.0 International (CC BY 4.0), which allows other people to freely distribute the published work with a mandatory reference to the authors of the original work and the first publication of the work in this journal.
        By submitting a manuscript to the editorial office of the Journal ‘Morphologia’ authors agree to transfer the rights to protect and use the manuscript (all supplemental materials, particularly protected objects such as photos, drawings, diagrams, tables, etc.), including the reproduction in the press and distribution via the Internet; translation of the manuscript into any language; export and import of journal copies with the Authors’ article in order to make it available for public. Authors convey the rights mentioned above to the editorial office without any temporal or territorial limitation all over the world. 
        The Authors guarantee that they have the exclusive rights to use the material transferred to editorial office. Editors are not responsible to third parties for contraventions of warranty given by the Authors. The considered rights are transferred to the editorial office since the moment when the current issue is signed for publishing. Reproduction of materials published in the Journal by other individuals and legal entities is possible only with the consent of Editorial office, with the obligatory indication of the full bibliographic reference of the primary publication. The Authors reserve the right to use the published material, its fragments and parts for teaching materials, oral presentations, dissertation thesis prepararion with obligatory bibliographic citation of the original paper. Electron copy of the published article, downloaded from official journal web-site in .pdf format may be put by authors on the official web-site of their institutions, any other official resources with open access.